GLP-1
The drug class that ate the endocrinology textbook, told one patient-year at a time.
What started as a type-2 diabetes injectable is now the largest pharmacological intervention in modern weight management. The GLP-1 desk covers the trial data, the prescribing questions, the muscle-and-bone debates, and the long tail of patients who are not in any trial at all.
This Week's Feature
The GLP-1 Era Has Just Begun
A class of drugs built for diabetes has quietly become the largest pharmacological intervention in modern weight management. The next decade will decide whether that story ends in medicine — or in marketing.
Read the feature → GLP-1 Why Your Brain Is the Real Target of GLP-1 Drugs
The "gut hormone" framing misses the point. Four neuroscientists walk through where these drugs actually work — and why the hypothalamus matters more than the gut.
GLP-1 What We Still Don't Know About a Decade on Semaglutide
Ten years of published data. Hundreds of thousands of patient-years of exposure. And yet the questions that matter most to the people on these drugs — what happens to muscle, to bone density, to the brain, to the hunger set point when you stop — have not been answered by anyone with an incentive to ask them.
GLP-1 The Quiet Reason GLP-1s Keep Working After You Stop Eating
The satiety story is the marketing story. The actual mechanism is weirder, slower, and harder to reproduce with lifestyle interventions — which is why the drugs work where discipline fails.
GLP-1 Dosing, Re-Dosing, and the Maintenance Question
What happens to patients who taper, stop, and restart? The observational data is messier than the trials and more relevant to real-world practice. Here is what a clinician should actually expect.